Abstract
After 2 weeks of intravenous challenge with Mycobacterium simiae, ICR outbred mice were treated with clarithromycin, ofloxacin, or clarithromycin plus ethambutol for 4 weeks. All three therapy groups demonstrated a decrease in the level of infection in both the lungs and the spleen. There were no significant differences among the three treated groups in decreasing mycobacterial counts in the lungs; however, both ofloxacin and clarithromycin plus ethambutol were superior to clarithromycin alone in reducing the level of infection in the spleen. Results of the study suggest a potential role for these agents in the treatment of human M. simiae infection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell R. C., Higuchi J. H., Donovan W. N., Krasnow I., Johanson W. G., Jr Mycobacterium simiae. Clinical features and follow-up of twenty-four patients. Am Rev Respir Dis. 1983 Jan;127(1):35–38. doi: 10.1164/arrd.1983.127.1.35. [DOI] [PubMed] [Google Scholar]
- Huminer D., Dux S., Samra Z., Kaufman L., Lavy A., Block C. S., Pitlik S. D. Mycobacterium simiae infection in Israeli patients with AIDS. Clin Infect Dis. 1993 Sep;17(3):508–509. doi: 10.1093/clinids/17.3.508. [DOI] [PubMed] [Google Scholar]
- Karassova V., Weissfeiler J., Krasznay E. Occurrence of atypical mycobacteria in Macacus rhesus. Acta Microbiol Acad Sci Hung. 1965;12(3):275–282. [PubMed] [Google Scholar]
- Lavy A., Yoshpe-Purer Y. Isolation of Mycobacterium simiae from clinical specimens in Israel. Tubercle. 1982 Dec;63(4):279–285. doi: 10.1016/s0041-3879(82)80016-0. [DOI] [PubMed] [Google Scholar]
- Lévy-Frébault V., Pangon B., Buré A., Katlama C., Marche C., David H. L. Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol. 1987 Jan;25(1):154–157. doi: 10.1128/jcm.25.1.154-157.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rastogi N., Goh K. S., David H. L. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother. 1990 May;34(5):759–764. doi: 10.1128/aac.34.5.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rastogi N., Goh K. S., Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother. 1992 Dec;36(12):2843–2846. doi: 10.1128/aac.36.12.2843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rastogi N., Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Mar;35(3):462–470. doi: 10.1128/aac.35.3.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rose H. D., Dorff G. J., Lauwasser M., Sheth N. K. Pulmonary and disseminated Mycobacterium simiae infection in humans. Am Rev Respir Dis. 1982 Dec;126(6):1110–1113. doi: 10.1164/arrd.1982.126.6.1110. [DOI] [PubMed] [Google Scholar]
- Torres R. A., Nord J., Feldman R., LaBombardi V., Barr M. Disseminated mixed Mycobacterium simiae-Mycobacterium avium complex infection in acquired immunodeficiency syndrome. J Infect Dis. 1991 Aug;164(2):432–433. doi: 10.1093/infdis/164.2.432. [DOI] [PubMed] [Google Scholar]
- Watson S. R., Auclair L. K., Collins F. M. The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice. Immunology. 1981 Jul;43(3):459–465. [PMC free article] [PubMed] [Google Scholar]